BIIB vs DNLI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BIIB and DNLI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BIIB and DNLI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases.

Full BIIB guide

Denali Therapeutics (NASDAQ: DNLI) is a South San Francisco biotechnology company built around its proprietary Transport Vehicle (TV) platform, an engineered antibody-fragment technology that binds transferrin receptors to shuttle enzymes, antibodies, proteins, and oligonucleotides across the blood-brain barrier after intravenous dosing. The lead product, AVLAYAH (tividenofusp alfa-eknm), received U.S. FDA accelerated approval in March 2026 for the neurologic manifestations of Hunter syndrome (MPS II) and began U.S. commercial distribution in April 2026, making it the first brain-penetrant enzyme replacement therapy in a class where the incumbent, Takeda's Elaprase, does not reach the central nervous system. The approval also came with a Rare Pediatric Disease Priority Review Voucher, a transferable asset that can be sold or used.

Full DNLI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.
• DNLI drivers: AVLAYAH commercial launch; Transport Vehicle platform breadth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. For DNLI, denali remains deeply unprofitable, posting a Q1 2026 net loss of roughly $128 million with heavy ongoing R&D spend, so it depends on its cash balance, partnerships, and future financings.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BIIB if you believe its drivers more; DNLI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BIIB and DNLI guides.

BIIB. Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.

DNLI. Denali is valued like a clinical-to-commercial platform biotech rather than on earnings, since AVLAYAH only launched in April 2026 and product revenue is just beginning; most historical revenue has been collaboration income. With about $1.05 billion in cash against a roughly $128 million quarterly loss, the balance sheet funds the launch and pipeline for now. Sell-side ratings skew bullish with an average target well above the recent price, reflecting launch and pipeline optionality rather than current profitability.

Headline figures (approximate, MAY 2026): BIIB shows revenue (ttm) ~$9.7B, q1 2026 revenue ~$2.5B (up ~2% YoY), q1 2026 non-gaap eps ~$3.57, market cap ~$29B; DNLI shows market cap ~$3.9B, share price ~$25, cash & marketable securities ~$1.05B, q1 2026 net loss ~$128M.

BIIB and DNLI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BIIB and DNLI exposure against your real portfolio. It is not an investment adviser.